Physician profile

Julia Ansari

Interventional Cardiology · Joplin, MO

NPI 1780846881

$24,308.71

in general payments reported to CMS, 2019-2025

37 companies · $1,895 in 2025

The $1,895 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$5,949.05
Food and Beverage$5,040.37

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $10,673.37 2019-2025 Watchman Flx, Watchman Access System, General - Ep
Medtronic, INC. $4,917.73 2021-2025 Corevalve Evolut R, Advisa Dr Mri Surescan, Azure Xt Dr Mri Surescan
Abbott Laboratories $1,871.04 2020-2025 Amplatzer, Cardiomems, Jot Dx
Abiomed $1,760.15 2019-2025 Impella
Penumbra, INC. $861.43 2023 Indigo System
Biosense Webster, INC. $748.83 2023-2025 Carto 3, Nuvision Ice Catheter, Octaray Mapping Catheter
Inari Medical, INC. $527.05 2022-2024 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Boehringer Ingelheim Pharmaceuticals, INC. $373.93 2021-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $274.87 2020-2024 Lifevest
Novartis Pharmaceuticals Corporation $261.69 2022-2025
Medtronic Vascular, INC. $251.74 2019-2020
Pfizer INC. $226.58 2020-2024
Edwards Lifesciences Corporation $216.35 2019-2025
Janssen Pharmaceuticals, INC $206.87 2021-2023 Xarelto
Recor Medical INC $189.75 2024 Paradise Renal Denervation System
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Cvrx, INC. $159.06 2022-2023 Barostim Neo System
Regeneron Healthcare Solutions, INC. $112.76 2019
Philips North America LLC $72.80 2025 Azurion 7 M20
Astrazeneca Pharmaceuticals LP $71.14 2021-2022
Merck Sharp & Dohme LLC $68.83 2022-2024 Verquvo
Alnylam Pharmaceuticals INC. $56.42 2025 Amvuttra
Amgen INC. $38.90 2021-2025 Repatha
Actelion Pharmaceuticals US, INC. $38.24 2023-2025 Uptravi, Opsumit, Opsynvi
Irhythm Technologies, INC. $34.97 2024 Zio Xt Patch
Titan Surgical Group, LLC $33.86 2025
E.R. Squibb & Sons, L.L.C. $33.15 2023 Camzyos
Novo Nordisk INC $31.15 2025 Wegovy
Itamar Medical INC $28.34 2024 Watchpatone
Kiniksa Pharmaceuticals International, Plc $26.05 2024 Arcalyst
Grifols USA, LLC $20.88 2024 Prolastin-C Liquid
Lantheus Medical Imaging, INC. $20.40 2019
Kestra Medical Technology Services, INC. $19.03 2025 Assure Wcd
Bayer Healthcare Pharmaceuticals INC. $18.94 2024
Inspire Medical Systems, INC. $18.46 2024 Inspire
Gilead Sciences, INC. $17.35 2019
Atricure, INC. $13.77 2024
Kowa Pharmaceuticals America, INC. $12.83 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Julia Ansari

$24,308.71

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $1,895 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/307780/julia-ansari

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.